Resveratrol Supplementation in Schizophrenia Patients: A Randomized Clinical Trial Evaluating Serum Glucose and Cardiovascular Risk Factors

被引:46
|
作者
Zortea, Karine [1 ,2 ]
Franco, Viviane C. [1 ,2 ]
Francesconi, Lenise P. [1 ,2 ]
Cereser, Keila M. M. [1 ,2 ]
Lobato, Maria Ines R. [1 ,2 ]
Belmonte-de-Abreu, Paulo S. [1 ,2 ]
机构
[1] Hosp Clin Porto Alegre, Schizophrenia Program, BR-90035903 Porto Alegre, RS, Brazil
[2] Univ Fed Rio Grande do Sul, Postgrad Program Med Psychiat, BR-90035903 Porto Alegre, RS, Brazil
来源
NUTRIENTS | 2016年 / 8卷 / 02期
关键词
cardiovascular disease; cholesterol; resveratrol; schizophrenia; METAANALYSIS;
D O I
10.3390/nu8020073
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background: Patients with schizophrenia (SZ) are generally overweight or obese and have several metabolic disorders. Additionally, such patients have a lower life expectancy and the main cause of their increased mortality is cardiovascular disease (CVD). The objective of this study was to determine the efficacy of resveratrol supplementation on serum glucose and CVD risk factors in individuals with SZ. Methods and Results: This is a four-week randomized, double-blind controlled trial (registration No.: NCT 02062190) in which 19 men with a diagnosis of SZ, aged 18 to 65, were assigned to either a resveratrol supplement group (200 mg/day) or a placebo group (200 mg/day). In short, we did not observe significant changes after resveratrol supplementation. In the placebo group, we found a significant increase in total cholesterol levels (p = 0.024) and in LDL-cholesterol (p = 0.002), as well as a decrease in body fat percentage (p = 0.038). The placebo group also showed an increase in triglycerides (9.19%) and a reduction in HDL-cholesterol (4.88%). In the resveratrol group, triglycerides decreased (7.64%). Conclusion: In summary, oral resveratrol in reasonably low dosages (200 mg daily) brought no differences to body weight, waist circumference, glucose, and total cholesterol. It was possible to note that the lipid profile in the placebo group worsened and, although no significant differences were found, we can assume that resveratrol might prevent lipid profile damage and that the intervention affected the lipoprotein metabolism at various levels.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Protocol for a randomized controlled trial to test the acceptability and adherence to 6-months of walnut supplementation in Chinese adults at high risk of cardiovascular disease
    Liu, Yishu
    Li, Nan
    Yan, Ni
    Pan, Xiong-fei
    Li, Qiang
    Micha, Renata
    Mozaffarian, Dariush
    Huffman, Mark D.
    Wang, Yanfang
    Neal, Bruce
    Tian, Maoyi
    Zhao, Yi
    Wu, Jason H. Y.
    NUTRITION JOURNAL, 2021, 20 (01)
  • [42] The prevalence, risk factors, and clinical characteristics of insulin resistance in Chinese patients with schizophrenia
    Lin, Chen
    Chen, Ke
    Zhang, Rongzhen
    Fu, Weihong
    Yu, Jianjin
    Gao, Lan
    Ni, Haiqing
    Song, Jiaqi
    Chen, Dachun
    COMPREHENSIVE PSYCHIATRY, 2020, 96
  • [43] The effect of bupropion on sexual function in patients with Schizophrenia: A randomized clinical trial
    Rezaei, O.
    Fadai, F.
    Sayadnasiri, M.
    Palizvan, M. A.
    Armoon, B.
    Noroozi, M.
    EUROPEAN JOURNAL OF PSYCHIATRY, 2018, 32 (01): : 11 - 15
  • [44] The effect of periodontal therapy on cardiovascular risk markers: a 6-month randomized clinical trial
    Caula, Andre Luis
    Lira-Junior, Ronaldo
    Barretto Tinoco, Eduardo Muniz
    Fischer, Ricardo Guimaraes
    JOURNAL OF CLINICAL PERIODONTOLOGY, 2014, 41 (09) : 875 - 882
  • [45] Effects of a Fixed-Dose Combination Strategy on Adherence and Risk Factors in Patients With or at High Risk of CVD The UMPIRE Randomized Clinical Trial
    Thom, Simon
    Poulter, Neil
    Field, Jane
    Patel, Anushka
    Prabhakaran, Dorairaj
    Stanton, Alice
    Grobbee, Diederick E.
    Bots, Michiel L.
    Reddy, K. Srinath
    Cidambi, Raghu
    Bompoint, Severine
    Billot, Laurent
    Rodgers, Anthony
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 310 (09): : 918 - 929
  • [46] Effect of L-Carnitine Supplementation on Inflammatory Markers and Serum Glucose in Hemodialysis Children: A Randomized, Placebo-Controlled Clinical Trial
    Hamedi-kalajahi, Fatemeh
    Imani, Hossein
    Mojtahedi, SayedYousef
    Shabbidar, Sakineh
    JOURNAL OF RENAL NUTRITION, 2022, 32 (02) : 144 - 151
  • [47] Effects of a multicomponent intervention on cardiovascular risk factors in overweight children: a randomized clinical trial in light of complex systems
    Bezerra, Thayna Alves
    de Souza Filho, Anastacio Neco
    Pessoa, Maria Luiza Felix
    Ribeiro Bandeira, Paulo Felipe
    Cabral, Luciana Gatto Azevedo
    de Moraes, Jose Fernando Vila Nova
    Martins, Clarice Maria de Lucena
    Carvalho, Ferdinando Oliveira
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL HEALTH RESEARCH, 2023, 33 (12) : 1368 - 1378
  • [48] Resveratrol Adjunct Therapy for Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial
    Samaei, Areoo
    Moradi, Kamyar
    Bagheri, Sayna
    Ashraf-Ganjouei, Amir
    Alikhani, Rosa
    Mousavi, Seiedeh Bentolhoda
    Rezaei, Farzin
    Akhondzadeh, Shahin
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2020, 23 (12): : 775 - 782
  • [49] Schizophrenia, bipolar disorder and major depressive disorder are probably not risk factors for cardiovascular disease: A Mendelian randomized study
    Chen, Jin
    Duan, Wenhuan
    Liu, Peizi
    Long, Cui
    Li, Aoyu
    Zhang, Xiangrong
    Zuo, Xiaowei
    JOURNAL OF AFFECTIVE DISORDERS, 2025, 377 : 184 - 196
  • [50] Associations of oxidative stress status parameters with traditional cardiovascular disease risk factors in patients with schizophrenia
    Vidovic, Bojana
    Stefanovic, Aleksandra
    Milovanovic, Srdan
    Dordevic, Brizita
    Kotur-Stevuljevic, Jelena
    Ivanisevic, Jasmina
    Miljkovic, Milica
    Spasic, Slavica
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2014, 74 (03): : 184 - 191